Can cannabis help with migraine? One controlled trial found that a THC-and-CBD cannabis formulation outperformed placebo for several short-term migraine outcomes, while the evidence for preventing future migraine attacks is still much less settled. If migraine is disrupting your days, the useful next step is to separate relief during an attack from prevention between attacks, then bring your symptom history and treatment goals to an appropriate clinician.
What controlled evidence exists for cannabis and migraine?
The clearest controlled evidence in this set is a 2026 randomized, double-blind, placebo-controlled crossover trial published in Headache. It enrolled 92 adults with migraine and recorded 247 treated attacks. At two hours, the THC-plus-CBD formulation had higher rates of pain relief, pain freedom, and freedom from the participant’s most bothersome symptom than placebo. The study also reported sustained pain-freedom results at 24 hours and sustained most-bothersome-symptom freedom at 24 and 48 hours.
That is an important result, but it answers a narrow question: what happened for attacks treated in that short crossover study. It does not answer what happens with frequent or long-term use, and it does not establish a prevention plan. The trial reported no serious adverse events, but it did not examine the long-term effects of frequent use.
| Study or review | Population | Formulation and comparator | Outcome measured | Duration | Harms reported | What the result can tell you |
|---|---|---|---|---|---|---|
| Headache, 2026 | 92 adults with migraine; 247 attacks treated | Vaporized THC-dominant, CBD-dominant, THC-plus-CBD, and placebo cannabis flower in randomized order | Pain relief, pain freedom, and most-bothersome-symptom freedom | Two-hour primary assessment; sustained outcomes through 48 hours | No serious adverse events | Higher short-term outcomes for THC plus CBD than placebo; CBD-dominant was not superior to placebo for the listed two-hour outcomes |
| Frontiers in Neurology, 2022 | 1,980 adults across 12 publications in Italy and the United States | Medical-cannabis studies; comparisons varied, including amitriptyline and non-cannabis products | Migraine days, frequency, nausea and vomiting, and attack outcomes | Reported outcomes at 30 days and six months in included publications | Medication-overuse headaches; adverse events, mostly mild, in 43.75% of oral-cannabinoid users | Promising findings, with a need for well-designed experimental studies |
| Current Pain and Headache Reports, 2021 | Review of the migraine literature | Cannabis and cannabinoid studies | Migraine profile and common coexisting concerns | Varied across the literature | Most reported side effects described as mild | Limited research and not enough data for specific dose recommendations |
| Current Pain and Headache Reports, 2023 | Review of cannabis and cannabinoid therapies in migraine and headache disorders | Varied cannabis and cannabinoid therapies | Efficacy, safety, tolerability, and clinical considerations | Varied across the literature | Potential pitfalls reviewed | Preliminary evidence exists, but further randomized controlled studies are needed |
How is relief during an attack different from prevention?
Acute relief means trying to reduce the pain or other symptoms of a migraine attack that is already happening. Prevention means trying to reduce how often attacks occur over time. The 2026 acute-migraine trial measured results after individual attacks, chiefly at two hours, so it belongs in the acute-relief conversation.
Prevention needs a different kind of study: people need to be followed over time, with migraine days or attack frequency measured against a comparator. The 2022 systematic review reported reductions in migraine days and monthly frequency in its included publications, but its authors also called for well-designed experimental studies. The 2023 review likewise describes the evidence as preliminary and calls for further randomized controlled research. In plain terms, the controlled evidence can tell you more about short-term attack outcomes than about a dependable prevention approach.
Keep a clear record of your attack frequency, symptoms, what you have already tried, and what outcome matters most to you. That gives a clinician something concrete to work with when you discuss relief versus prevention.
What did the controlled trial actually find?
In the 2026 trial, THC plus CBD was superior to placebo for pain relief at two hours: 67.2% versus 46.6%. It was also superior for pain freedom at two hours, 34.5% versus 15.5%, and for freedom from the most bothersome symptom, 60.3% versus 34.5%. THC-dominant cannabis was superior to placebo for pain relief, but not for the other two-hour outcomes. CBD-dominant cannabis was not superior to placebo for the listed two-hour outcomes.
Those figures describe the formulations and outcomes used in that one trial. They are not a reason to assume that every cannabis product, hemp product, gummy, or label will produce the same result. For a plain-language look at the biology behind these compounds, see the endocannabinoid system.
What should you know about safety while you weigh this option?
Cannabis can affect people differently based on THC concentration, product ingredients, other drugs, health conditions, age, and prior experience, according to the CDC’s cannabis overview. THC is impairing or mind-altering, while CBD by itself is not impairing, the CDC says.
The National Institute on Drug Abuse says THC-containing products can change mood, thoughts, and perception, and can affect thinking, memory, and body movement. It also says cannabis can increase heart rate and blood pressure right after use. If you take medicines or have health concerns that could matter here, bring that full medication list and health history to the clinician conversation.
The migraine-specific 2022 review reported medication-overuse headaches and mostly mild adverse events among people using oral cannabinoid preparations. That matters because a migraine plan should account for what may happen when a product is used repeatedly, not only what happens during one attack. If cannabis is not helping or the situation is becoming harder to manage, when cannabis is not helping explains practical next steps.
What does federal law say as of October 5, 2026?
As of the October 5, 2026 capture date, the FDA’s cannabis regulation page says the Agriculture Improvement Act of 2018, Pub. L. 115-334, signed December 20, 2018, defines hemp as Cannabis sativa L. and its covered derivatives with no more than 0.3% delta-9 THC on a dry-weight basis. The law preserved FDA authority over products containing cannabis-derived compounds under the Federal Food, Drug, and Cosmetic Act.
The FDA also says it has not approved the cannabis plant for any medical use, and that THC and CBD products cannot legally be sold as dietary supplements under its current interpretation. State and local rules can differ, so this is information, not legal advice; check the rules where you live before making a decision.
Before you make a cannabis-for-migraine decision
- Bring a symptom history: how often attacks happen, how long they last, and which symptoms interfere with your day.
- State your goal clearly: short-term relief during an attack, fewer attacks over time, or both.
- Bring your current medicines and health history so a clinician can discuss possible interactions and safety concerns.
- Ask which outcomes are realistic to track and when the plan should be reassessed.
- Ask how your state’s rules apply to the specific product category you are considering.
By TakeHempGummies.com Consumer Research Desk
This article is for general information purposes only and does not constitute medical advice. Consult your doctor or qualified healthcare provider before making changes to your health routine.